{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:29Z","timestamp":1786120349816,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/wnf.0b013e3182372526","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T04:16:44Z","timestamp":1319516204000},"page":"220-223","source":"Crossref","is-referenced-by-count":1,"title":["Medication Phobia"],"prefix":"10.1097","volume":"34","author":[{"given":"Ilana","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1136\/jnnp.2010.213652","article-title":". Depression and anxiety related subtypes in Parkinsons disease.","volume":"82","author":"Brown","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.22833","article-title":". Anxiety disorders in Parkinsons disease: prevalence and risk factors.","volume":"15","author":"Dissanayaka","year":"2010","journal-title":"Mov Disord"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.22760","article-title":". Anxious and depressive symptoms in Parkinsons disease: the French cross-sectional DoPaMiP study.","volume":"25","author":"Negre-Pages","year":"2010","journal-title":"Mov Disord"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1212\/01.WNL.0000152880.77812.5B","article-title":"Levodopa phobia: a new iatrogenic cause of disability in Parkinson disease.","volume":"64","author":"Kurlan","year":"2005","journal-title":"Neurology"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/mds.21831","article-title":". Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinsons disease.","volume":"15","author":"Kulkarni","year":"2008","journal-title":"Mov Disord"},{"key":"R8-5-20210203","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1468-1331.2010.03320.x","article-title":". Socio-demographic and clinical factors influencing the adherence to treatment in Parkinsons disease: the ADHESON study.","volume":"18","author":"Valldeoriola","year":"2010","journal-title":"Eur J Neurol"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/WNL.0b013e3181d55f24","article-title":". Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"16","author":"Zesiewicz","year":"2010","journal-title":"Neurology"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201111000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:54Z","timestamp":1786047894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201111000-00005"}},"subtitle":["A New Cause of Drug Noncompliance in Parkinson Disease"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3182372526","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}